Dianthus Therapeutics, Inc. /DE/ (DNTH) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -192.25M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-192.25M | (m) |
| 2026-03-31 | (m) | $-173.66M | (m) |
| 2025-12-31 | (m) | $-162.34M | (m) |
| 2025-09-30 | (m) | $-126.34M | (m) |
| 2025-06-30 | (m) | $-114.75M | (m) |
| 2025-03-31 | (m) | $-100.73M | (m) |
| 2024-12-31 | (m) | $-84.97M | (m) |
| 2024-09-30 | (m) | $-67.09M | (m) |
| 2024-06-30 | (m) | $-56.68M | (m) |
| 2024-03-31 | (m) | $-50.21M | (m) |
| 2023-12-31 | (m) | $-43.55M | (m) |
| 2023-09-30 | (m) | $-91.13M | (m) |
| 2023-06-30 | (m) | $-68.73M | (m) |
| 2023-03-31 | (m) | $-82.72M | (m) |
| 2022-12-31 | (m) | $-76.46M | (m) |
| 2022-09-30 | (m) | $-75.54M | (m) |
| 2022-06-30 | (m) | $-76.90M | (m) |
| 2022-03-31 | (m) | $-76.56M | (m) |
| 2021-12-31 | (m) | $-71.14M | (m) |
| 2021-09-30 | (m) | $-69.98M | (m) |
| 2021-06-30 | (m) | $-70.23M | (m) |
| 2021-03-31 | (m) | $-72.38M | (m) |
| 2020-12-31 | (m) | $-74.94M | (m) |
| 2020-09-30 | (m) | $-80.04M | (m) |
| 2020-06-30 | (m) | $-83.35M | (m) |
| 2020-03-31 | (m) | $-81.98M | (m) |
| 2019-12-31 | (m) | $-76.77M | (m) |
| 2019-09-30 | (m) | $-70.20M | (m) |
| 2019-06-30 | (m) | $-65.22M | (m) |
| 2019-03-31 | (m) | $-61.17M | (m) |
| 2018-12-31 | (m) | $-57.52M | (m) |
| 2018-09-30 | (m) | $22.12M | (m) |
| 2018-06-30 | (m) | $31.22M | (m) |
| 2018-03-31 | (m) | $-41.84M | (m) |
| 2017-12-31 | (m) | $35.50M | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) |
| 2016-12-31 | (m) | $-9.43M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |